

Tomoki Ito

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/200657/publications.pdf>

Version: 2024-02-01

97
papers

5,655
citations

236925

25
h-index

76900

74
g-index

102
all docs

102
docs citations

102
times ranked

7467
citing authors

#	ARTICLE	IF	CITATIONS
1	TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. <i>Journal of Experimental Medicine</i> , 2005, 202, 1213-1223.	8.5	952
2	Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. <i>Journal of Experimental Medicine</i> , 2007, 204, 105-115.	8.5	569
3	TSLP: An Epithelial Cell Cytokine that Regulates T Cell Differentiation by Conditioning Dendritic Cell Maturation. <i>Annual Review of Immunology</i> , 2007, 25, 193-219.	21.8	566
4	Two Functional Subsets of FOXP3+ Regulatory T Cells in Human Thymus and Periphery. <i>Immunity</i> , 2008, 28, 870-880.	14.3	488
5	Interferon- γ and Interleukin-12 Are Induced Differentially by Toll-like Receptor 7 Ligands in Human Blood Dendritic Cell Subsets. <i>Journal of Experimental Medicine</i> , 2002, 195, 1507-1512.	8.5	434
6	Maintenance and Polarization of Human TH2 Central Memory T Cells by Thymic Stromal Lymphopoietin-Activated Dendritic Cells. <i>Immunity</i> , 2006, 24, 827-838.	14.3	295
7	Differential Regulation of Human Blood Dendritic Cell Subsets by IFNs. <i>Journal of Immunology</i> , 2001, 166, 2961-2969.	0.8	279
8	Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. <i>Blood</i> , 2006, 107, 2423-2431.	1.4	248
9	Plasmacytoid dendritic cell precursors/type I interferon-producing cells sense viral infection by Toll-like receptor (TLR) 7 and TLR9. <i>Seminars in Immunopathology</i> , 2005, 26, 221-229.	4.0	174
10	OX40 ligand shuts down IL-10-producing regulatory T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 13138-13143.	7.1	170
11	Plasmacytoid Dendritic Cells Regulate Th Cell Responses through OX40 Ligand and Type I IFNs. <i>Journal of Immunology</i> , 2004, 172, 4253-4259.	0.8	162
12	Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL). <i>Blood</i> , 2006, 107, 3617-3623.	1.4	132
13	Guanosine and its modified derivatives are endogenous ligands for TLR7. <i>International Immunology</i> , 2016, 28, 211-222.	4.0	97
14	IL-33 Promotes the Induction and Maintenance of Th2 Immune Responses by Enhancing the Function of OX40 Ligand. <i>Allergology International</i> , 2014, 63, 443-455.	3.3	90
15	Cellular and Molecular Mechanisms of TSLP Function in Human Allergic Disorders - TSLP Programs the γ Th2 code in Dendritic Cells. <i>Allergology International</i> , 2012, 61, 35-43.	3.3	76
16	Dendritic Cells Are Decreased in Blood and Accumulated in Granuloma in Tuberculosis. <i>Clinical Immunology</i> , 2002, 105, 296-303.	3.2	72
17	Functional Diversity and Plasticity of Human Dendritic Cell Subsets. <i>International Journal of Hematology</i> , 2005, 81, 188-196.	1.6	59
18	Roles of toll-like receptors in natural interferon-producing cells as sensors in immune surveillance. <i>Human Immunology</i> , 2002, 63, 1120-1125.	2.4	53

#	ARTICLE	IF	CITATIONS
19	A New Method for Bone Marrow Cell Harvesting. <i>Stem Cells</i> , 2000, 18, 453-456.	3.2	49
20	Alteration of peripheral blood dendritic cells in patients with primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2001, 44, 419-431.	6.7	48
21	ICOSLG-mediated regulatory T cell expansion and IL-10 production promote progression of glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 333-344.	1.2	40
22	Delayed HBV reactivation in rituximab-containing chemotherapy: How long should we continue anti-virus prophylaxis or monitoring HBV-DNA?. <i>Leukemia Research</i> , 2016, 50, 46-49.	0.8	38
23	Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production. <i>Arthritis and Rheumatism</i> , 2010, 62, 2073-2085.	6.7	37
24	Associations between acute GVHD-related biomarkers and endothelial cell activation after allogeneic hematopoietic stem cell transplantation. <i>Transplant Immunology</i> , 2017, 43-44, 27-32.	1.2	34
25	GM-CSF therapy inhibits chronic graft-versus-host disease via expansion of regulatory T cells. <i>European Journal of Immunology</i> , 2019, 49, 179-191.	2.9	30
26	Inhibitor of ÎB kinase activity, BAY 11-7082, interferes with interferon regulatory factor 7 nuclear translocation and type I interferon production by plasmacytoid dendritic cells. <i>Arthritis Research and Therapy</i> , 2010, 12, R87.	3.5	24
27	Imidazoquinoline Acts as Immune Adjuvant for Functional Alteration of Thymic Stromal Lymphopoietin-Mediated Allergic T Cell Response. <i>Journal of Immunology</i> , 2008, 181, 5340-5349.	0.8	23
28	Experimental Autoimmune Thyroiditis Induced by Thyroglobulin-Pulsed Dendritic Cells. <i>Autoimmunity</i> , 1999, 31, 273-282.	2.6	22
29	Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era. <i>Hematology Reports</i> , 2017, 9, 16-18.	0.8	20
30	The prevalence of endoscopic gastric mucosal damage in patients with rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0200023.	2.5	17
31	A Hodgkin's Disease Cell Line, KM-H2, Shows Biphenotypic Features of Dendritic Cells and B Cells. <i>International Journal of Hematology</i> , 2001, 73, 236-244.	1.6	16
32	Development of Mouse Dendritic Cells from Lineage-Negative c-kit ^{low} Pluripotent Hemopoietic Stem Cells In Vitro. <i>Stem Cells</i> , 2000, 18, 53-60.	3.2	15
33	Platelet-derived RANK ligand enhances CCL17 secretion from dendritic cells mediated by thymic stromal lymphopoietin. <i>Platelets</i> , 2015, 26, 425-431.	2.3	15
34	Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment of essential thrombocythemia patients in a real-world setting. <i>European Journal of Haematology</i> , 2019, 103, 116-123.	2.2	15
35	Statins can suppress DC-mediated Th2 responses through the repression of OX40 ligand and CCL17 expression. <i>European Journal of Immunology</i> , 2019, 49, 2051-2062.	2.9	13
36	Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses. <i>Blood Advances</i> , 2020, 4, 3572-3585.	5.2	13

#	ARTICLE	IF	CITATIONS
37	A case of rheumatoid pericarditis associated with a high IL-6 titer in the pericardial fluid and tocilizumab treatment. <i>Modern Rheumatology</i> , 2011, 21, 302-304.	1.8	12
38	TGF β 21 and sCTLA-4 levels are increased in eltrombopag-exposed patients with ITP. <i>Thrombosis Research</i> , 2012, 130, 415-419.	1.7	11
39	Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arteriosclerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study). <i>Vascular Health and Risk Management</i> , 2018, Volume 14, 225-232.	2.3	11
40	Neutrophil-to-lymphocyte ratio (NLR) fails to predict outcome of diffuse large B cell lymphoma. <i>Leukemia Research Reports</i> , 2019, 12, 100173.	0.4	11
41	Mycophenolic acid, the active form of mycophenolate mofetil, interferes with IRF7 nuclear translocation and type I IFN production by plasmacytoid dendritic cells. <i>Arthritis Research and Therapy</i> , 2020, 22, 264.	3.5	11
42	Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation. <i>Journal of Blood Medicine</i> , 2016, 7, 1.	1.7	10
43	Enhanced international prognostic index in Japanese patients with diffuse large B-cell lymphoma. <i>Leukemia Research Reports</i> , 2016, 6, 24-26.	0.4	10
44	<p>Extracellular Vesicle-Related Thrombosis in Viral Infection</p>. <i>International Journal of General Medicine</i> , 2020, Volume 13, 559-568.	1.8	10
45	Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis. <i>European Journal of Haematology</i> , 2020, 105, 704-711.	2.2	10
46	Successful treatment with plasma exchange in adult-onset Still's disease with hyper-IL-18-naemia and hyperallergic state. <i>Modern Rheumatology</i> , 2008, 18, 407-410.	1.8	9
47	Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma. <i>Journal of Blood Medicine</i> , 2018, Volume 9, 1-7.	1.7	9
48	<p>The immunomodulatory-drug, lenalidomide, sustains and enhances interferon- β production by human plasmacytoid dendritic cells</p>. <i>Journal of Blood Medicine</i> , 2019, Volume 10, 217-226.	1.7	9
49	Adult T-cell leukemia after immunosuppressive therapy for systemic lupus erythematosus. <i>International Journal of Hematology</i> , 2009, 89, 128-129.	1.6	8
50	Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endothelin receptor antagonist bosentan monotherapy: two case reports. <i>Journal of Medical Case Reports</i> , 2014, 8, 250.	0.8	8
51	Combined Use of Ninjin'yoeto Improves Subjective Fatigue Caused by Lenalidomide in Patients With Multiple Myeloma: A Retrospective Study. <i>Frontiers in Nutrition</i> , 2018, 5, 72.	3.7	8
52	Successful treatment with plasma exchange in adult-onset Still's disease with hyper-IL-18-naemia and hyperallergic state. <i>Modern Rheumatology</i> , 2008, 18, 407-410.	1.8	8
53	Successful treatment with mogamulizumab followed by allogeneic hematopoietic stem-cell transplantation in adult T-cell leukemia/lymphoma: a report of two cases. <i>International Journal of Hematology</i> , 2016, 104, 744-748.	1.6	7
54	Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan. <i>Journal of Blood Medicine</i> , 2017, Volume 8, 5-12.	1.7	7

#	ARTICLE	IF	CITATIONS
55	Evaluation of eltrombopag in patients with aplastic anemia in real-world experience. <i>Leukemia Research Reports</i> , 2019, 11, 11-13.	0.4	7
56	Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study. <i>International Journal of Hematology</i> , 2022, 115, 208-221.	1.6	7
57	Upfront high-dose chemotherapy combined with autologous stem cell transplantation: Potential survival benefit for patients with high-risk diffuse large B-cell lymphoma. <i>Oncology Letters</i> , 2017, 14, 3803-3808.	1.8	6
58	Clinical significance of dasatinib-induced pleural effusion in patients with de novo chronic myeloid leukemia. <i>Hematology Reports</i> , 2018, 10, 7474.	0.8	6
59	Effects of recombinant thrombomodulin on long-term prognosis after allogeneic hematopoietic stem cell transplantation. <i>Transplant Immunology</i> , 2019, 57, 101247.	1.2	5
60	Effects of recombinant thrombomodulin therapy and soluble human leukocyte antigen-G levels during hematopoietic stem cell transplantation. <i>Transplant Immunology</i> , 2019, 53, 28-33.	1.2	5
61	Multiple Myeloma with Central Nervous System Relapse Early after Autologous Stem Cell Transplantation: A Case Report and Literature Review. <i>Internal Medicine</i> , 2021, 60, 463-468.	0.7	5
62	Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 660.e1-660.e8.	1.2	5
63	Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study. <i>European Journal of Haematology</i> , 2022, 109, 58-68.	2.2	5
64	Disseminated intravascular coagulation observed following treatment with gemtuzumab ozogamicin for relapsed/refractory acute promyelocytic leukemia. <i>Molecular and Clinical Oncology</i> , 2016, 5, 31-34.	1.0	4
65	Dasatinib-induced hemorrhagic colitis complicated with cytomegalovirus infection. <i>Hematology Reports</i> , 2017, 9, 7415.	0.8	4
66	Assessment of soluble cytotoxic T lymphocyte-associated antigen-4, transforming growth factor β , and platelet-derived microparticles during dasatinib therapy for patients with chronic myelogenous leukemia. <i>Journal of Blood Medicine</i> , 2019, Volume 10, 1-8.	1.7	4
67	Secondary pure red cell aplasia in multiple myeloma treated with lenalidomide. <i>Leukemia Research Reports</i> , 2018, 10, 4-6.	0.4	4
68	Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-naïve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg/day. <i>International Journal of Hematology</i> , 2020, 112, 33-40.	1.6	4
69	Usefulness of Cytokine Gene Polymorphisms for the Therapeutic Choice in Japanese Patients with Rheumatoid Arthritis. <i>International Journal of General Medicine</i> , 2021, Volume 14, 131-139.	1.8	4
70	Alteration of peripheral blood dendritic cells in patients with primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2001, 44, 419-431.	6.7	4
71	Recombinant Thrombomodulin for the Treatment of Transplantation-Associated Coagulopathy after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 5089-5089.	1.4	4
72	Establishment of a tumor sphere cell line from a metastatic brain neuroendocrine tumor. <i>Medical Molecular Morphology</i> , 2017, 50, 211-219.	1.0	3

#	ARTICLE	IF	CITATIONS
73	Refractory Chronic Lymphocytic Leukemia with Central Nervous System Involvement: A Case Report with Literature Review. <i>Journal of Blood Medicine</i> , 2020, Volume 11, 487-502.	1.7	3
74	Analysis of HLA haplotype and clinical factors during hematopoietic stem cell transplantation. <i>Transplant Immunology</i> , 2021, 66, 101376.	1.2	2
75	Elotuzumab Enhances the Th2-Mediated Immune Response of Dendritic Cell Induced By Immunomodulatory Drugs (IMiDs). <i>Blood</i> , 2019, 134, 4342-4342.	1.4	2
76	Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy. <i>International Journal of Hematology</i> , 2022, 116, 89-101.	1.6	2
77	Mogamulizumab treatment of refractory peripheral T-cell lymphoma following autologous stem cell transplantation: A case report. <i>Molecular and Clinical Oncology</i> , 2016, 4, 151-153.	1.0	1
78	Human T-cell leukemia virus type δ † associated with an increased risk of primary malignant neoplasm. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017, 10, 2018024.	1.3	1
79	Transplant-Ineligible Symptomatic but Indolent Multiple Myeloma Shows Better Prognosis with Conventional Agents. <i>Case Reports in Oncology</i> , 2018, 10, 871-875.	0.7	1
80	Blastic Epstein-Barr virus associated post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation for severe aplastic anemia. <i>Hematology Reports</i> , 2018, 10, 7527.	0.8	1
81	Effect of Cytokine Gene Polymorphisms on Eltrombopag Reactivity in Japanese Patients with Immune Thrombocytopenia. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 421-429.	1.7	1
82	Evaluation of azacitidine in patients with transplant-ineligible myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes in a Japanese clinical setting. <i>Oncology Letters</i> , 2020, 19, 1317-1321.	1.8	1
83	Retrospective analysis of adolescent and young adult with lymphoma at two cancer facilities in Japan. <i>Leukemia Research Reports</i> , 2019, 12, 100174.	0.4	0
84	Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum. <i>EJHaem</i> , 2021, 2, 765-773.	1.0	0
85	Dendritic cell functions in innate and adaptive immunity. <i>The Journal of the Japanese Society of Lymphoreticular Tissue Research</i> , 2000, 40, 175-184.	0.0	0
86	Recombinant Thrombomodulin For The Treatment Of Transplantation-Associated Coagulopathy After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 5454-5454.	1.4	0
87	Evaluation Of Large Granular Lymphocytes and Endothelial-Cell-Related Biomarkers In Patients With Chronic Myeloblastic Leukemia: Comparison Among 3 TKIs. <i>Blood</i> , 2013, 122, 5167-5167.	1.4	0
88	Origin, differentiation, function, and distribution of dendritic cells.. <i>The Journal of the Japanese Society of Lymphoreticular Tissue Research</i> , 1999, 39, 163-173.	0.0	0
89	Recombinant Thrombomodulin for the Treatment of Transplantation-Associated Coagulopathy after Allogeneic Hematopoietic Stem Cell Transplantation: A Multi-Center Study in Japan. <i>Blood</i> , 2015, 126, 4341-4341.	1.4	0
90	Immunomodulatory Drugs (IMiDs), Lenalidomide and Pomalidomide, Suppress Th1-Inducing Capacity of Dendritic Cells but Enhance Th2-Mediated Allergic Response. <i>Blood</i> , 2016, 128, 2520-2520.	1.4	0

#	ARTICLE	IF	CITATIONS
91	A Critical Role of Host-Derived Semaphorin-4A for Regulating T Cell Immune Responses in Acute Graft Versus Host Disease. <i>Blood</i> , 2018, 132, 3322-3322.	1.4	0
92	Does Neutrophil to Lymphocyte Ratio (NLR) Predict the Prognosis of Diffuse Large B-Cell Lymphoma?. <i>Blood</i> , 2018, 132, 5402-5402.	1.4	0
93	Myeloma Cells Have the Ability to Suppress Th1-Inducing Capacity but Enhance Th2-Mediated Response of Dendritic Cells By Producing Factors Other Than Soluble SLAMF7. <i>Blood</i> , 2018, 132, 1938-1938.	1.4	0
94	Trend of salvage treatment in diffuse large B cell lymphoma in the outpatient chemotherapy era. <i>Molecular and Clinical Oncology</i> , 2019, 11, 557-562.	1.0	0
95	Plasma Biomarker Predicts Lethal Acute Graft Versus Host Disease and Non-Relapse Mortality in Japanese Patients. <i>Blood</i> , 2019, 134, 5672-5672.	1.4	0
96	DETECTION OF IRREGULAR ANTIBODIES BY LISS-IAT DURING BLOOD TRANSFUSION THERAPY: TWO CASE REPORTS. <i>Japanese Journal of Transfusion and Cell Therapy</i> , 2019, 65, 870-875.	0.2	0
97	Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) in the Treatment of Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma; Integrated Analysis of Three Japanese Institution's Experience with Improvement Trend of the Long-Term Responses over a 10 Year Study Period. <i>Blood</i> , 2020, 136, 9-10.	1.4	0